ARCHIVES

Also in this 8-page issue: Richard Pazdur named director of FDA’s new Office of Oncology Drug Products.

This article is from The Cancer Letter archive.

Vol. 31 No. 16 | April 22, 2005

Download PDF Visit The Full Archive

Related Articles

Proteomics Used To Find Predictor Of Response In FAP

April 30, 2004

Growth Of The Cost of Drugs Slows to 5.4 Percent per Year; 21 Therapies Launched in 2 Years

May 9, 2014

Science Agencies Seek To Measure Effect Of Research Funding

June 4, 2010

Duke Deans Acknowledge Withholding Key Document From Outside Reviewers

January 14, 2011

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

January 27, 2012

Oral Contraceptives Related To Liver Tumors; New Studies Urged

March 12, 1976